KPTI
KaryopharmยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
KPTI Profile
Karyopharm Therapeutics Inc.
A commercial-stage pharmaceutical company pioneering novel cancer therapies
Biological Technology
12/22/2008
11/06/2013
NASDAQ Stock Exchange
279
12-31
Common stock
85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459
--
Karyopharm Therapeutics Inc., was incorporated in Delaware on December 22, 2008. The company is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-line drugs targeting nuclear transport targets for the treatment of cancer and critical diseases. The company's scientific expertise focuses on understanding the regulation of intracellular transport between the nucleus and cytoplasm. The company discovers and develops wholly-owned, novel, small molecule, nuclear export selective inhibitor or SINE compounds that inhibit the nuclear export protein XPO 1. The company's lead drug candidate, Selinexor (KPT-330), an XPO 1 inhibitor, is being evaluated in multiple open-label Phase 1 clinical trials in patients with advanced pretreatment of relapsed and refractory hematologic and solid tumor malignancies.
